Biotech Values

[AlpineBV_Miller]

DNDN would probably be wise not to overplay their hand and set too high a price.

While I trust the diligent work Dendreon has done on the market in terms of pricing, I see this as the biggest risk to a successful launch. I think Dendreon would do better to set a price largely independent of what others have set for their own biologics.

Of course, I still think Genentech and ImClone are idiots for their pricing of Avastin and Erbitux.